Status:
COMPLETED
Chronic Obstructive Pulmonary Disease Endpoints Study
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40+ years
Phase:
PHASE4
Brief Summary
This study will last for approximately 14 weeks and will involve 5 visits. The study is being carried out to look at different ways of measuring the effect of drug treatment on COPD. COPD is a respira...
Detailed Description
Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease (COPD) in a Randomized, Double-Blind, Placebo-Controlled Study of Treatment with Fluticasone Propionate/Salmeterol ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis of COPD
- Current or ex-smoker at least 10 pack- years
- Exclusion criteria:
- Diagnosis of asthma
- Active respiratory disorder other than COPD
- Evidence of clinically significant uncontrolled non-pulmonary disease
- Carcinoma not in complete remission for last 5 years
- Lung volume reduction surgery in previous 12 months
- Nocturnal positive pressure for sleep apnea
- Other inclusion and exclusion criteria will be evaluated at the first study visit.
Exclusion
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2007
Estimated Enrollment :
163 Patients enrolled
Trial Details
Trial ID
NCT00358358
Start Date
March 1 2006
End Date
February 1 2007
Last Update
January 20 2017
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Absecon, New Jersey, United States, 8201
2
GSK Investigational Site
Charleston, South Carolina, United States, 29406-7108
3
GSK Investigational Site
Greenville, South Carolina, United States, 29615
4
GSK Investigational Site
Spartanburg, South Carolina, United States, 29303